Descriptive analysis of MS patients converting from Natalizumab (Tysabri) IV to SC formulation in Finnish register data.

This is a a descriptive real-world evidence study, which aims to characterize Finnish MS patients treated SC formulation of natalizumab.

Changes to the permit: addition of variables